Clinical trials: Metastasis Colorectal Cancer
Colorectal Cancer Metastatic, Survival Rate
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
The body immunity is important to the development of tumor. The immune system is in charge of monitoring and cleaning tumor cells in circulation. Anesthesia may alter the immune response and affect the elimination of tumor cells.
- Conditions
- Colorectal Cancer Metastatic, Survival Rate, General Anesthetics Toxicity, Lymphocyte Destruction
- Trial name
- NCT03193710
- Testing
- Propofol, Sevoflurane, Remifentanil
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Guizhi Du
Metastases
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM…
- Trial name
- NCT05195710
- Testing
- Yttrium-90 (Y-90) resin microspheres
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Liver Metastasis
Postoperative Exercise Training in Patients With Colorectal Liver Metastases Undergoing Surgery (ELMA)
Surgery is a primary treatment modality in the intended curative treatment of colorectal liver metastases (CRLM). However, surgery elicits a cascade of potentially detrimental stress responses that may drive the onset of…
- Trial name
- ELMA (NCT04751773)
- Testing
- Exercise training
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphomas, Solid Tumors
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Background: Methoxyamine hydrochloride (TRC102) is a new cancer treatment drug that may help improve the results of chemotherapy.
- Conditions
- Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma
- Trial name
- NCT01851369
- Testing
- TRC102, CT scan, Lomotil
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer
- Trial name
- NCT00004095
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Colorectal Cancer
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
- Trial name
- ABX067 (NCT00625573)
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Solid Cancer
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
The primary objective of this study is to evaluate the safety of TSA-CTL in the treatment of advanced solid tumors. The secondary objective of this study is to evaluate preliminarily the effect of TSA-CTL in the treatment of…
- Trial name
- NCT02959905
- Testing
- TSA-CTL, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 11 people
- Sponsor
- BGI, China
Colo-rectal Cancer
Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting…
- Trial name
- NCT03476122
- Where
- Taiwan
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- CellMaxLife
Colorectal Cancer Metastatic, Liver Metastases
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases, resection should be…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer
- Trial name
- BOS3 (NCT01646554)
- Testing
- Modified FOLFOX6, Aflibercept, Surgery
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer Metastatic
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- NCT04031872
- Testing
- LY3200882
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer Metastatic
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
This Phase II research project will test the efficacy, safety, and tolerability of an experimental drug combination: either nivolumab and BBI608 or nivolumab and BNC105 in patients with metastatic colorectal cancer who have…
- Trial name
- MODULATE (NCT03647839)
- Testing
- Nivolumab 10 MG/ML, BNC 105, BBI608
- Where
- 14 sites in Australia
- Volunteers
- 90 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Colorectal Cancer
Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006037
- Testing
- fluorouracil, irinotecan hydrochloride, oglufanide disodium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Southern California
Colorectal Cancer
Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
In this study, patients will receive either pemetrexed plus irinotecan or 5-fluorouracil (5-FU), leucovorin, and irinotecan. The purposes of this study are to determine: How pemetrexed plus irinotecan compares with 5-FU…
- Trial name
- NCT00079872
- Testing
- Pemetrexed
- Where
- 6 sites in Australia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer Liver Metastases
Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient
Establishment and validation of the deep learning model of Cetuximab efficacy in simultaneous RAS wild unresectable CRLM patients
- Trial name
- NCT05873972
- Testing
- Cetuximab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
Primary Objective: To evaluate the improvement in progression-free survival (PFS) of aflibercept versus placebo in participants with metastatic colorectal cancer treated with FOLFIRI as second-line treatment for metastatic…
- Trial name
- AFLAME (NCT01661270)
- Testing
- Aflibercept
- Where
- 37 sites in China, Hong Kong and 3 more
- Volunteers
- 332 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
This is an observational study in which data already collected from people with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part…
- Trial name
- RegoSeq (NCT06137170)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Colorectal Cancer
Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer
RATIONALE: Drugs used in chemotherapy such as epothilone D work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077259
- Testing
- epothilone D
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
MSI, dMMR Colorectal Cancer
Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
MSI is a molecular indicator of defective DNA mismatch repair (dMMR). The MSI/dMMR status is observed in all tumor types, representing notably 5% of metastatic colorectal cancers (mCRC), 25% of advanced endometrial cancer and 8%…
- Trial name
- MONAMI (NCT06152523)
- Testing
- Monalizumab/MEDI5257
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.